Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Clinical experience with recently approved antibiotics.

David L Paterson1

  • 1Division of Infectious Diseases, University of Pittsburgh Medical Center, Suite 3A, Falk Medical Building, 3601 5th Avenue, Pittsburgh, PA 15213, USA. patersond@dom.pitt.edu

Current Opinion in Pharmacology
|August 15, 2006
PubMed
Summary

New antibiotics combat resistant bacteria like vancomycin-resistant enterococci and Staphylococcus aureus. While some agents like quinupristin/dalfopristin have limitations, linezolid, daptomycin, and tigecycline offer effective treatments, with more novel drugs in development.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Correction: Achievement of therapeutic antibiotic exposures using Bayesian dosing software in critically unwell children and adults with sepsis.

Intensive care medicine·2024
Same author

<i>Pseudomonas stutzeri</i> bloodstream infection is a prevailing community-onset disease with important mortality rates: results from a retrospective observational study in Australia.

Infectious diseases (London, England)·2024
Same author

Achievement of therapeutic antibiotic exposures using Bayesian dosing software in critically unwell children and adults with sepsis.

Intensive care medicine·2024
Same author

Comparing Polymerase Chain Reaction Testing of Nasopharyngeal Swab and Lower Respiratory Tract Specimens for the Diagnosis of <i>Pneumocystis jirovecii</i> Pneumonia.

Open forum infectious diseases·2024
Same author

Antibacterial agents active against Gram Negative Bacilli in phase I, II, or III clinical trials.

Expert opinion on investigational drugs·2024
Same author

Host response signature trends in bacteraemia - authors' response.

Infectious diseases (London, England)·2024

Area of Science:

  • Microbiology
  • Infectious Diseases
  • Pharmacology

Background:

  • The rise of vancomycin-resistant enterococci and Staphylococcus aureus necessitated the development of novel antimicrobial agents.
  • Existing treatments faced challenges due to resistance and adverse effects, driving innovation in antibiotic discovery.

Purpose of the Study:

  • To review new antimicrobial agents developed to combat resistant Gram-positive pathogens.
  • To evaluate the efficacy, limitations, and clinical utility of recently introduced antibiotics.

Main Methods:

  • Literature review of clinical studies and pharmacological data for new antibiotics.
  • Comparative analysis of antimicrobial spectrum, mechanism of action, and clinical applications.
  • Assessment of pharmacokinetic and pharmacodynamic properties, including tissue penetration and surfactant interactions.

Related Experiment Videos

Main Results:

  • Quinupristin/dalfopristin, though an early agent, has limited use due to adverse effects.
  • Linezolid (oxazolidinone class) offers broad use with oral and IV formulations.
  • Daptomycin is effective against S. aureus bloodstream infections but not pneumonia due to surfactant inactivation.
  • Tigecycline exhibits broad-spectrum bacteriostatic activity and good tissue penetration.

Conclusions:

  • Several new antibiotics have emerged to address challenging Gram-positive infections.
  • Each new agent possesses unique properties, advantages, and limitations influencing their clinical application.
  • Ongoing development of antibiotics like dalbavancin, telavancin, ceftobiprole, and doripenem promises future therapeutic options.